Breathe BioMedical is identifying composite biomarkers for routine early disease screening.

Our breath is full of chemicals called Volatile Organic Compounds (VOCs) which are produced by metabolic processes in our bodies. These compounds can reveal a great deal about the clinical state of an individual’s health, environmental exposure, and about metabolic changes.   

Breath analysis allows for timely screening which benefits practitioners in identifying health issues early, which will lead to saving healthcare resources, and more importantly, saving lives. Breathe BioMedical’s technology is being developed to be able to screen for biomarkers of cancer, neurologic and respiratory diseases often long before symptoms appear. 

Our platform combines three advanced technologies to sample, digitize and analyze breath to screen for disease. 

 

Sample

Just breathe® and we’ll collect a breath sample ready for the lab.

LEARN MORE

Digitize

Breath samples are translated into spectral data sets using our advanced infrared spectrometer. 

LEARN MORE

Analyze

Our machine learning algorithm identifies disease biomarkers contained within the spectral data sets.   

We're Starting with Lung Cancer, the Deadliest Cancer in the World

14.5 Million Americans are eligible for annual lung cancer screening; however, only 5-15% of those eligible get screened. Currently, Breathe BioMedical has completed a proof-of-concept study for lung cancer and is continuing work with independent research partners in Canada and the USA. Our initial studies have demonstrated accuracy of 86.1% for detecting lung cancer in breath.

Cancer 
Screening

Lung Cancer
Breast Cancer
Liver Cancer
Colorectal Cancer

Neurodegenerative
Diseases

Alzheimer’s Disease
Parkinson’s Disease
Dementia

Respiratory
Diseases

COPD
Tuberculosis
Asthma

Personalized
Medicine

Drug Choice and Dosing
Drug Effectiveness Monitoring
Companion Diagnostics